Skip to main content
HairCited

미녹시딜 관련 안드로겐성 탈모

A

총 41,495명의 참여자를 대상으로 한 191건의 연구(메타분석 19건, RCT 21건)에 근거합니다. 191건 중 159건의 연구에서 긍정적인 효과가 나타났습니다.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'ingredient\u003Dminoxidil\u0026condition\u003Dandrogenetic\u002Dalopecia'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

결론

Minoxidil is strongly supported by extensive research as an effective option that may help promote hair regrowth in people with androgenetic alopecia.

  • 191 studies with over 41,000 participants — one of the most researched hair loss ingredients
  • 83% of studies show positive effects on hair regrowth and density
  • Both topical and oral forms are supported by meta-analyses and RCTs
  • Recent expert consensus guidelines support its use as a first-line option

Key Study Findings

Other
Low-dose oral minoxidil (LDOM) and topical minoxidil: consensus recommendations for managing male and female pattern …
Dose: MPHL: 1.25-2.5 mg/day; FPHL: 0.625-1.25 mg/day vs: None Outcome: consensus recommendations for managing pattern hair loss 효과: None None

대상 집단: hair transplant patients with male and female pattern hair loss (Delphi panel consensus)

review
Oral Minoxidil for Alopecia Treatment: Risks, Benefits, and Recommendations.
Dose: Oral minoxidil: women 1.25 mg/day starting dose (range 0.625-5 mg/day); men 2.5 mg/day (range 1.25-5 vs: Placebo 효과: Comparable efficacy to topical minoxidil; hypertrichosis 24%, shedding 16-22%, peripheral edema 2% None
Review
Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments.
Dose: None vs: None Outcome: None 효과: None None

대상 집단: women with androgenetic alopecia (female pattern hair loss)

non-randomized controlled trial n=60 16 weeks Open-label
Clinical Efficacy and Mechanisms of Microneedling Alone or Combined With Drugs in the Treatment of …
Dose: Mild group: microneedling alone (8 weeks); Moderate group: microneedling + 5% minoxidil (12 weeks); vs: Placebo 효과: All groups showed significant decrease in HLSS and increase in hair density post-treatment (p<0.001) p<0.001
Review
Male and female pattern hair loss.
Dose: None vs: Placebo 효과: None None

Key Statistics

299

연구

68291

참여자

Positive

A

등급

Referenced Papers

Journal of the … 2026
Aesthetic plastic surgery 2025 14 인용
Anais brasileiros de … 2025 7 인용
Acta dermato-venereologica 2025 4 인용
European journal of … 2025 3 인용
Australian prescriber 2025 2 인용
Acta dermatovenerologica Alpina, … 2025 2 인용
Skin appendage disorders 2025 1 인용
Journal of clinical … 2025 1 인용
International journal of … 2025 1 인용
Annals of dermatology 2025
Nature reviews. Disease … 2025
Archives of dermatological … 2025
International journal of … 2024 39 인용
Indian journal of … 2024 14 인용
Journal of cosmetic … 2024 11 인용
Journal of clinical … 2024 10 인용
Photodermatology, photoimmunology & … 2024 8 인용
Facial plastic surgery … 2024 8 인용
American family physician 2024 8 인용
Skin health and … 2024 7 인용
International journal of … 2024 5 인용
SAGE open medical … 2024 3 인용
Vestnik oftalmologii 2024 1 인용
Drugs 2023 221 인용
JAAD international 2023 80 인용
Clinical, cosmetic and … 2023 58 인용
American journal of … 2023 41 인용
Anais brasileiros de … 2023 29 인용
Skin appendage disorders 2023 27 인용
Archives of dermatological … 2023 16 인용
Journal der Deutschen … 2023 5 인용
Journal of cosmetic … 2023 3 인용
BMJ case reports 2023 2 인용
Clinics in plastic … 2023 1 인용
International journal of … 2023 1 인용
The Journal of … 2022 170 인용
Faculty reviews 2022 44 인용
Dermatologic therapy 2022 41 인용
Journal of cosmetic … 2022 35 인용
Journal of cosmetic … 2022 7 인용
Cureus 2022 3 인용
Facial plastic surgery … 2022
Journal of cutaneous … 2021 44 인용
Journal of the … 2021 42 인용
Actas dermo-sifiliograficas 2021 3 인용
Expert opinion on … 2020 147 인용
American journal of … 2020 127 인용
International journal of … 2020 58 인용
Indian dermatology online … 2020 31 인용
Dermatologic clinics 2020 15 인용
Facial plastic surgery … 2020 15 인용
Alternative therapies in … 2020 11 인용
Drug design, development … 2019 320 인용
Journal of cosmetic … 2019 100 인용
American journal of … 2019 84 인용
Expert opinion on … 2019 34 인용
Bioscience, biotechnology, and … 2019 9 인용
Journal of the … 2018 114 인용
Indian journal of … 2018 79 인용
Dermatologic therapy 2018 63 인용
Australian journal of … 2018 8 인용
American family physician 2017 141 인용
JAMA dermatology 2017 121 인용
Current clinical pharmacology 2017 62 인용
Actas dermo-sifiliograficas 2017 17 인용
BMJ case reports 2017 6 인용
Deutsches Arzteblatt international 2016 99 인용
The Cochrane database … 2016 18 인용
Current problems in … 2015 8 인용
Der Internist 2015
Expert opinion on … 2014 57 인용
Skin therapy letter 2014 29 인용
Giornale italiano di … 2014 8 인용
Giornale italiano di … 2014
Indian journal of … 2013 196 인용
Dermatologic clinics 2013 78 인용
Journal of cosmetic … 2013 62 인용
International journal of … 2013 61 인용
Facial plastic surgery … 2013 16 인용
Indian journal of … 2013 16 인용
International journal of … 2013
The Cochrane database … 2012 15 인용
Expert opinion on … 2010 264 인용
Current opinion in … 2009 54 인용
Seminars in cutaneous … 2009 4 인용
American family physician 2009
Current opinion in … 2008 31 인용
Nihon rinsho. Japanese … 2008 6 인용
Endocrinology and metabolism … 2007 33 인용
Clinical interventions in … 2007
Acta dermatovenerologica Alpina, … 2005
Annual review of … 2004 664 인용
Revue medicale de … 2004
The journal of … 2003 102 인용
Praxis 2003 28 인용
American family physician 2003 2 인용
American family physician 2003
Clinical and experimental … 2002 61 인용
Therapeutische Umschau. Revue … 2002 4 인용
American journal of … 2000 18 인용
Southern medical journal 2000
International journal of … 1999 16 인용
International journal of … 1999
American family physician 1999
Journal of the … 1999
Journal of cutaneous … 1999
Dermatologic clinics 1998 121 인용
Annales de dermatologie … 1997
Journal of the … 1984

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

일반적으로 사용되는 용량

topical:
2-5% solution, twice daily

상한량: 5% topical solution

연구에서 사용된 용량

용량 기간 효과 N
MPHL: 1.25-2.5 mg/day; FPHL: 0.625-1.25 mg/day -- Positive --
Oral minoxidil: women 1.25 mg/day starting dose (range 0.625-5 mg/day); men 2.5 mg/day (range 1.25-5 -- Positive --
None -- Neutral --
Mild group: microneedling alone (8 weeks); Moderate group: microneedling + 5% minoxidil (12 weeks); 16 weeks Positive 60
None -- Positive --
None -- Positive --
None -- Positive 11
not specified -- Positive --

권장 복용 시간: Apply to dry scalp morning and evening, at least 4 hours before bed

Safety & Side Effects

보고된 부작용

  • Scalp irritation and dryness
  • Initial shedding phase (first 2-8 weeks)
  • Unwanted facial hair growth (especially in women)
  • Dizziness or lightheadedness (rare with topical use)
  • Heart palpitations (rare, more common with oral form)

알려진 상호작용

  • Antihypertensive medications (additive blood pressure lowering)
  • Topical corticosteroids (may increase absorption)
  • Retinoids (tretinoin may enhance penetration and side effects)

일일 최대 섭취 허용량: 5% topical solution

건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.

Frequently Asked Questions

Does 미녹시딜 help with 안드로겐성 탈모?
Based on 299 studies with 68,291 participants, there is strong evidence from multiple clinical trials that 미녹시딜 may support 안드로겐성 탈모 management. Our evidence grade is A (Strong Evidence).
How much 미녹시딜 should I take for 안드로겐성 탈모?
Studies have used various dosages. A commonly studied range is 2-5% solution, twice daily. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of 미녹시딜?
Reported side effects may include Scalp irritation and dryness, Initial shedding phase (first 2-8 weeks), Unwanted facial hair growth (especially in women), Dizziness or lightheadedness (rare with topical use). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for 미녹시딜 and 안드로겐성 탈모?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 299 peer-reviewed studies with 68,291 total participants. The overall direction of effect is positive.

Related Evidence

FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.